Form 4: Astria Therapeutics Executive Andrea Matthews Reports Stock Option Grant
SEC Form 4 Filing
Andrea Matthews, Chief Business Officer of Astria Therapeutics, reports the grant of stock options for 262,500 shares.
Summary
- On March 21, 2025, Andrea Matthews, the Chief Business Officer of Astria Therapeutics, Inc., was granted stock options to purchase 262,500 shares of common stock.
- The exercise price of the options is $6.41 per share.
- The options vest over a four-year period, starting with 25% vesting on February 13, 2026, and the remainder vesting in equal monthly installments over the following three years.
- Following the transaction, Matthews directly owns options for 262,500 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. This grant is typical for a Chief Business Officer role.
Comparison to Industry Standards
- Stock option grants for Chief Business Officers in biotech companies of similar size to Astria Therapeutics typically range from 0.1% to 0.5% of outstanding shares.
- Vesting schedules of four years with a one-year cliff are standard practice in the industry, similar to companies like BioCryst Pharmaceuticals and Sarepta Therapeutics.
Stakeholder Impact
- The stock option grant incentivizes the Chief Business Officer to drive company growth, potentially benefiting shareholders.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | First anniversary for vesting calculation. |
| 03/21/2025 | Date of stock option grant. |
| 03/25/2025 | Date of signature on the Form 4 filing. |
| 02/13/2026 | First vesting date (25% of options). |
| 03/20/2035 | Expiration date of the stock options. |
Keywords
stock options, Astria Therapeutics, Form 4, executive compensation, insider trading, ATXS, Andrea Matthews, Chief Business Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.